Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis

@inproceedings{Wang2016EfficacyAS,
  title={Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis},
  author={Li Wang and Zhe Gao and Xiaoping Chen and Hai-yan Zhang and Nan Yang and Fei-yan Wang and Li-xun Guan and Zhen-yang Gu and Sha-sha Zhao and Lan Luo and Hua-ping Wei and Chun-ji Gao},
  booktitle={Scientific reports},
  year={2016}
}
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and impaired platelet production. In this study, we conducted a systematic review and meta-analysis to determine the efficacy and safety of thrombopoietin receptor agonists (TPO-RAs) in primary ITP patients. Thirteen randomized controlled trials were included in this study, the pooled results of which demonstrated that TPO-RAs significantly increased platelet response (R) and durable response… CONTINUE READING